Table 3.

Biodistribution data obtained in IGROV-1 tumor-bearing mice, 24 h after injection of [¹⁷⁷Lu]folate with and without pre- and post-injected pemetrexed (PMX). Data are shown as % IA/g tissue, representing the average ± S.D.

	[177Lu]cm13
	-	PMX (1)	PMX (2)	PMX (3)
	24 h p.i.	24 h p.i.	24 h p.i.	24 h p.i.
Tissue	IGROV-1	IGROV-1	IGROV-1	IGROV-1
	n = 4	n = 5	n = 5	n = 5
Blood	1.46 ± 0.19	1.97 ± 0.15	2.21 ± 0.29	2.08 ± 0.31
Lung	1.88 ± 0.24	2.16 ± 0.23	2.23 ± 0.25	2.21 ± 0.33
Spleen	0.92 ± 0.17	1.19 ± 0.26	1.26 ± 0.33	1.20 ± 0.30
Kidneys	34.0 ± 2.00	26.2 ± 3.50 ***	21.8 ± 2.00 ****	20.8 ± 3.40 **** (4)
Stomach	0.69 ± 0.19	0.69 ± 0.31	0.78 ± 0.13	0.65 ± 0.17
Intestines	0.49 ± 0.12	0.44 ± 0.08	0.48 ± 0.07	0.43 ± 0.14
Liver	2.75 ± 0.57	2.47 ± 0.51	2.73 ± 0.65	2.41 ± 0.49
Muscle	1.52 ± 0.19	1.36 ± 0.37	1.28 ± 0.52	1.28 ± 0.32
Bone	0.95 ± 0.11	0.96 ± 0.12	1.02 ± 0.17	0.95 ± 0.10
Tumor	37.7 ± 5.10	40.7 ± 9.00	38.6 ± 3.50	32.9 ± 5.30 (5)
Salivary glands	4.43 ± 0.63	4.28 ± 0.43	3.95 ± 1.03	3.77 ± 0.45

⁽¹⁾ PMX (400 µg/mouse) was injected 1 h prior to the [¹⁷⁷Lu]folate; ⁽²⁾ PMX (twice 400 µg/mouse) was injected 1 h prior to the [¹⁷⁷Lu]folate and 3 h after [¹⁷⁷Lu]folate; ⁽³⁾ PMX (twice 400 µg/mouse) was injected 1 h prior to the [¹⁷⁷Lu]folate and 7 h after [¹⁷⁷Lu]folate. ⁽⁴⁾ This value was significantly different from the value obtained in mice that received PMX 1 h before the radiofolate; ⁽⁵⁾ This value was significantly different from the values obtained in mice that received PMX 1 h before (and 3 h after) the radiofolate. Statistical significance is indicated with asterisks (statistically significant difference between uptake in the tissue of control mice and PMX injected mice. *** p ≤ 0.001; **** p ≤ 0.0001).